Opus Genetics, Inc.

IRD ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Assets
Cash & Equivalents $45.1M $30.3M $50.5M $42.6M $24.5M $16.4M $1.5M $8.7M
Accounts Receivable $2.0M $3.6M $926.0K $1.3M $0
Inventory
Total Current Assets $50.0M $36.6M $53.9M $49.0M $26.1M $17.7M $1.8M $15.9M
Property, Plant & Equipment $199.0K $252.0K $0 $6.0K $10.0K $14.0K $22.0K $112.5K
Goodwill
Intangible Assets (Excl. Goodwill)
Total Assets $50.2M $36.9M $53.9M $49.0M $26.1M $17.7M $1.8M $16.0M
Liabilities
Accounts Payable $3.3M $3.1M $2.2M $1.1M $1.6M $1.2M $342.0K
Total Current Liabilities $7.8M $11.3M $4.0M $2.8M $3.9M $3.2M $9.3M $3.2M
Long-Term Debt $1.1M $0
Total Liabilities $34.9M $11.3M $4.0M $2.8M $3.9M $31.1M $9.3M $5.5M
Stockholders' Equity
Retained Earnings $-188.6M $-139.0M $-81.5M $-71.5M $-89.4M $-32.7M $-8.1M $-154.7M
Total Stockholders' Equity $15.3M $6.7M $49.9M $46.2M $22.2M $-13.5M $-7.6M $-1.7M
← Newer Page 1 of 4 Older →